Dermafence

Company Overview

Snapshot

Founded in May 2017 by Dr. Shulamit Richter Dayan, Dermafence operates with 1–10 employees. The company has raised $20,000 across three funding rounds. In March 2018, Dermafence secured a Seed round with MassChallenge Israel as a lead investor.

Business overview

Dermafence is a Health Tech & Life Sciences company focused on developing a proprietary technology for burn treatment. Its core product is a first-aid burn formulation based on a GRAS (Generally Recognized As Safe) formulation with a novel mechanism of action. This technology is designed to prevent energy from penetrating deeper skin layers, thereby restoring and protecting epidermal skin barrier function after exposure to burn-inducing insults. The company serves the medical technologies market, targeting patients, doctors, and medical product sectors with B2C and B2B2C business models.

Company Intelligence Q&A

Who founded Dermafence?

Dermafence was founded by Dr. Shulamit Richter Dayan, who also serves as the CEO.

What is Dermafence's primary focus?

Dermafence primarily focuses on developing a proprietary technology for the treatment of burns, utilizing a GRAS formulation to protect and restore the skin barrier.

When was Dermafence founded?

Dermafence was founded in May 2017.

What was a significant early funding event for Dermafence?

In March 2018, Dermafence secured a Seed funding round, with MassChallenge Israel participating as a lead investor.

What is the total capital raised by Dermafence?

Dermafence has raised a total of $20,000 across three funding rounds.